Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The human intestinal and skin microbiota are vast, diverse ecosystems comprising trillions of microorganisms, including bacteria, fungi, viruses, and archaea, that reside on and within the human body [1]. The intestinal microbiota is essential for the fermentation of non-digestible dietary fibers into short-chain fatty acids, the synthesis of vitamins K and B12, and the maturation of the host immune system [2]. Similarly, the skin microbiota acts as a biological barrier, producing antimicrobial peptides and competing with pathogens to maintain skin health [3]. Disruptions in these communities, known as dysbiosis, are strongly associated with local and systemic diseases such as inflammatory bowel disease, obesity, and atopic dermatitis [4]. Therapeutic strategies targeting these microbiota include the use of probiotics, prebiotics, and fecal microbiota transplants to restore ecological balance and improve clinical outcomes [5].
Modulation of microbial community structure and metabolic output to restore host-microbe homeostasis [5].
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human intestinal and skin microbiota.